We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46,863

Are Drug Prices Really Too High?
  • Foley & Lardner LLP
  • USA
  • May 5 2016

Those working in the pharmaceutical space are used to hearing complaints about the high costs of drugs, and patents often are blamed for allowing


Seeing your first Medicare GME dollars
  • Dentons
  • USA
  • May 5 2016

Hospitals that decide to begin training residents and become new teaching hospitals often wonder when they will start to receive Medicare graduate


New and Disruptive Technologies: The Care and Feeding of the New Economy Expect Focus - Vol. I, Winter 2016
  • Carlton Fields
  • USA
  • May 5 2016

The Consumer Financial Protection Bureau (CFPB ) has taken its first UDAAP action against a consumer financial service provider related to data


New FTC Guidance and Tools for Mobile Medical Apps
  • Hall Render Killian Heath & Lyman PC
  • USA
  • May 5 2016

On Tuesday, April 5, the Federal Trade Commission ("FTC") released a new web-based tool for developers of health-related mobile apps. The tool asks


Higher Quality of Care Equals Higher Quantity of Payment in MACRA Proposed Rule
  • Hogan Lovells
  • USA
  • May 4 2016

Have they concocted the perfect Formula? Last week, the Centers for Medicare & Medicaid Services (CMS) took the next step toward creating a new


Cybersecurity concerns for ERISA fiduciaries, today’s General Counsel
  • Morgan Lewis & Bockius LLP
  • USA
  • May 4 2016

The F.B.I. now ranks cybercrime as one of its top law enforcement priorities, and President Obama's proposed budget would sharply increase spending


Genetic Tech. v. Merial: Laws of Nature and Genetic Testing Revisited
  • Baker Botts LLP
  • USA
  • May 4 2016

The Supreme Court has long held that laws of nature along with abstract ideas and natural phenomena are not patentable. In particular, the


Third Circuit Dismisses Antitrust Suit Concerning Marketing of Lovenox
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • May 4 2016

Earlier today, the Third Circuit Court of Appeals upheld the decision of the District of New Jersey trial court dismissing the antitrust claims


Don’t Discount the Discounts: Pfizer and Wyeth Reach Settlement Over Medicaid Drug Pricing Allegations
  • Arent Fox LLP
  • USA
  • May 4 2016

The Department of Justice recently announced it has reached a more than $780 million settlement with Pfizer Inc. and its subsidiary Wyeth to resolve


OIG Approves Another MedigapPreferred Hospital Network in Advisory Opinion 16-04
  • Ober Kaler
  • USA
  • May 4 2016

On April 18th, the OIG issued a new favorable Advisory Opinion, No. 16-04, regarding an agreement between a Medigap insurer and preferred hospital